Host: John J. Russell, MD

Guest: Jeanny Aragon-Ching, MD

Patients with advanced RCC often face poor outcomes, especially if they have one or more risk factors. To learn more about a treatment option for intermediate- or poor-risk patients, Dr. John Russell welcomes Dr. Jeanny Aragon-Ching, who discusses clinical trial findings and their potential impact in this disease state.

This promotional, non-CME program is intended for U.S. physicians treating advanced RCC. Dr. Aragon-Ching is a paid consultant of Bristol-Myers Squibb.

Indications

OPDIVO® (nivolumab), in combination with YERVOY® (ipilimumab), is indicated for the treatment of patients with intermediate or poor risk, previously untreated advanced renal cell carcinoma (RCC).

OPDIVO (10 mg/mL) and YERVOY (5 mg/mL) are injections for intravenous use.

Please see Important Safety Information for OPDIVO and YERVOY, including Boxed WARNING regarding immune-mediate adverse reactions for YERVOY, below.

Important Safety Information

WARNING: IMMUNE-MEDIATED ADVERSE REACTIONS

YERVOY can result in severe and fatal immune-mediated adverse reactions. These immune-mediated reactions may involve any organ system; however, the most common severe immune-mediated adverse reactions are enterocolitis, hepatitis, dermatitis (including toxic epidermal necrolysis), neuropathy, and endocrinopathy. The majority of these immune-mediated reactions initially manifested during treatment; however, a minority occurred weeks to months after discontinuation ...